rs4252120

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_000301.5(PLG):​c.1256+9T>C variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.259 in 1,609,930 control chromosomes in the GnomAD database, including 58,523 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.23 ( 4490 hom., cov: 32)
Exomes 𝑓: 0.26 ( 54033 hom. )

Consequence

PLG
NM_000301.5 intron

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:4

Conservation

PhyloP100: 0.666

Publications

70 publications found
Variant links:
Genes affected
PLG (HGNC:9071): (plasminogen) The plasminogen protein encoded by this gene is a serine protease that circulates in blood plasma as an inactive zymogen and is converted to the active protease, plasmin, by several plasminogen activators such as tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), kallikrein, and factor XII (Hageman factor). The conversion of plasminogen to plasmin involves the cleavage of the peptide bond between Arg-561 and Val-562. Plasmin cleavage also releases the angiostatin protein which inhibits angiogenesis. Plasmin degrades many blood plasma proteins, including fibrin-containing blood clots. As a serine protease, plasmin cleaves many products in addition to fibrin such as fibronectin, thrombospondin, laminin, and von Willebrand factor. Plasmin is inactivated by proteins such as alpha-2-macroglobulin and alpha-2-antiplasmin in addition to inhibitors of the various plasminogen activators. Plasminogen also interacts with plasminogen receptors which results in the retention of plasmin on cell surfaces and in plasmin-induced cell signaling. The localization of plasminogen on cell surfaces plays a role in the degradation of extracellular matrices, cell migration, inflamation, wound healing, oncogenesis, metastasis, myogenesis, muscle regeneration, neurite outgrowth, and fibrinolysis. This protein may also play a role in acute respiratory distress syndrome (ARDS) which, in part, is caused by enhanced clot formation and the suppression of fibrinolysis. Compared to other mammals, the cluster of plasminogen-like genes to which this gene belongs has been rearranged in catarrhine primates. [provided by RefSeq, May 2020]
PLG Gene-Disease associations (from GenCC):
  • hypoplasminogenemia
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, ClinGen, Genomics England PanelApp, Labcorp Genetics (formerly Invitae)
  • angioedema, hereditary, 4
    Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.78).
BP6
Variant 6-160722576-T-C is Benign according to our data. Variant chr6-160722576-T-C is described in ClinVar as [Benign]. Clinvar id is 1175041.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.287 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
PLGNM_000301.5 linkc.1256+9T>C intron_variant Intron 10 of 18 ENST00000308192.14 NP_000292.1 P00747

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
PLGENST00000308192.14 linkc.1256+9T>C intron_variant Intron 10 of 18 1 NM_000301.5 ENSP00000308938.9 P00747
PLGENST00000418964.2 linkc.1307+9T>C intron_variant Intron 10 of 18 4 ENSP00000389424.2 A6PVI2
PLGENST00000297289.9 linkc.209+9T>C intron_variant Intron 2 of 10 5 ENSP00000516619.1 A0A9L9PXP2
PLGENST00000706906.1 linkn.1256+9T>C intron_variant Intron 10 of 18 ENSP00000516618.1 A0A9L9PYG2

Frequencies

GnomAD3 genomes
AF:
0.232
AC:
35207
AN:
151918
Hom.:
4490
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.175
Gnomad AMI
AF:
0.222
Gnomad AMR
AF:
0.203
Gnomad ASJ
AF:
0.306
Gnomad EAS
AF:
0.00173
Gnomad SAS
AF:
0.103
Gnomad FIN
AF:
0.261
Gnomad MID
AF:
0.220
Gnomad NFE
AF:
0.291
Gnomad OTH
AF:
0.246
GnomAD2 exomes
AF:
0.215
AC:
53930
AN:
251306
AF XY:
0.217
show subpopulations
Gnomad AFR exome
AF:
0.178
Gnomad AMR exome
AF:
0.125
Gnomad ASJ exome
AF:
0.291
Gnomad EAS exome
AF:
0.000707
Gnomad FIN exome
AF:
0.260
Gnomad NFE exome
AF:
0.296
Gnomad OTH exome
AF:
0.234
GnomAD4 exome
AF:
0.262
AC:
381619
AN:
1457894
Hom.:
54033
Cov.:
30
AF XY:
0.259
AC XY:
187574
AN XY:
725508
show subpopulations
African (AFR)
AF:
0.171
AC:
5710
AN:
33422
American (AMR)
AF:
0.132
AC:
5887
AN:
44714
Ashkenazi Jewish (ASJ)
AF:
0.290
AC:
7579
AN:
26100
East Asian (EAS)
AF:
0.000529
AC:
21
AN:
39692
South Asian (SAS)
AF:
0.108
AC:
9289
AN:
86208
European-Finnish (FIN)
AF:
0.262
AC:
14011
AN:
53402
Middle Eastern (MID)
AF:
0.257
AC:
1464
AN:
5698
European-Non Finnish (NFE)
AF:
0.291
AC:
322750
AN:
1108396
Other (OTH)
AF:
0.247
AC:
14908
AN:
60262
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.472
Heterozygous variant carriers
0
11969
23938
35906
47875
59844
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
10270
20540
30810
41080
51350
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.232
AC:
35226
AN:
152036
Hom.:
4490
Cov.:
32
AF XY:
0.227
AC XY:
16887
AN XY:
74308
show subpopulations
African (AFR)
AF:
0.176
AC:
7280
AN:
41474
American (AMR)
AF:
0.203
AC:
3102
AN:
15286
Ashkenazi Jewish (ASJ)
AF:
0.306
AC:
1061
AN:
3468
East Asian (EAS)
AF:
0.00174
AC:
9
AN:
5178
South Asian (SAS)
AF:
0.103
AC:
496
AN:
4820
European-Finnish (FIN)
AF:
0.261
AC:
2754
AN:
10556
Middle Eastern (MID)
AF:
0.216
AC:
63
AN:
292
European-Non Finnish (NFE)
AF:
0.291
AC:
19747
AN:
67950
Other (OTH)
AF:
0.244
AC:
512
AN:
2102
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
1357
2714
4072
5429
6786
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
362
724
1086
1448
1810
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.268
Hom.:
23221
Bravo
AF:
0.228
Asia WGS
AF:
0.0530
AC:
188
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:2
-
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

not provided Benign:2
Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jun 19, 2021
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.78
CADD
Benign
15
DANN
Benign
0.58
PhyloP100
0.67
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.030
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs4252120; hg19: chr6-161143608; COSMIC: COSV51983668; API